Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.62 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | DRD4 | P21917 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 7/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.36 |
| ▸ | RELA | Q04206 | 5/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4622038 | 0.99 | AQP1 (0.61) | AQP1DRD2DRD4DRD3NFKB1 | |
| SCHEMBL14112703 | 0.88 | AQP1 (0.53) | AQP1DRD2DRD4DRD3NFKB1 | |
| SCHEMBL4224840 | 0.88 | AQP1 (0.79) | AQP1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL4224838 | 0.88 | AQP1 (0.79) | AQP1DRD2DRD4DRD3CHRM2 | |
| SCHEMBL14112697 | 0.88 | AQP1 (0.66) | AQP1DRD2DRD4DRD3NFKB1 | |
| SCHEMBL14112699 | 0.88 | AQP1 (0.80) | AQP1DRD2DRD4DRD3NFKB1 | |
| Hydrochloric Acid SCHEMBL4621235 | 0.87 | AQP1 (0.52) | AQP1DRD2DRD4DRD3NFKB1 | |
| SCHEMBL8258240 | 0.87 | AQP1 (0.48) | AQP1DRD2DRD4DRD3NFKB1 | |
| Hydrochloric Acid SCHEMBL4622016 | 0.87 | AQP1 (0.78) | AQP1DRD2DRD4DRD3NFKB1 | |
| Hydrochloric Acid SCHEMBL4621954 | 0.87 | AQP1 (0.65) | AQP1DRD2DRD4DRD3NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | AQP1 3318/4885DRD2 63/4885DRD4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.